ARTICLE | Clinical News
Aflibercept: Phase II data
June 9, 2008 7:00 AM UTC
In a Phase II trial, aflibercept missed the primary endpoint of 6-month PFS. One patient with glioblastoma multiforme (GBM) had 6-month PFS, and the study required >=8 GBM patients to be progression-f...